Search Articles
WILMINGTON, Del. – Directors are selling Ambit Biosciences too cheaply through an unfair process to Daiichi Sankyo, for $15 a share or $410 million, shareholders claim in a class action in Chancery Court.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.